Safety and Efficacy of YB-1113 in Treatment of POI
NCT05494723
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
6
Enrollment
INDUSTRY
Sponsor class
Conditions
POI
Interventions
DRUG:
YB-1113
Sponsor
Bright Cell, Inc.